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GOLPH2 is coding the 73-kDa type II Golgi membrane antigen GOLPH2/GP73. Upregulation of GOLPH2 mRNA has been recently
reported in expression array analyses of prostate cancer. As GOLPH2 protein expression in prostate tissues is currently unknown,
this study aimed at a comprehensive analysis of GOLPH2 protein in benign and malignant prostate lesions. Immunohistochemically
detected GOLPH2 protein expression was compared with the basal cell marker p63 and the prostate cancer marker a-methylacyl-
CoA racemase (AMACR) in 614 radical prostatectomy specimens. GOLPH2 exhibited a perinuclear Golgi-type staining pattern and
was preferentially seen in prostatic gland epithelia. Using a semiquantitative staining intensity score, GOLPH2 expression was
significantly higher in prostate cancer glands compared with normal glands (Po0.001). GOLPH2 protein was upregulated in 567 of
614 tumours (92.3%) and AMACR in 583 of 614 tumours (95%) (correlation coefficient 0.113, P¼0.005). Importantly, GOLPH2
immunohistochemistry exhibited a lower level of intratumoral heterogeneity (25 vs 45%). Further, GOLPH2 upregulation was
detected in 26 of 31 (84%) AMACR-negative prostate cancer cases. These data clearly suggest GOLPH2 as an additional ancillary
positive marker for tissue-based diagnosis of prostate cancer.
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The identification of sensitive and specific biomarkers in tissue
and serum is of utmost importance to reduce the mortality of
prostate cancer (Parekh et al, 2007). Expression arrays, SNP
analyses and mass spectrometry are new tools for biomarker
identification (Zheng et al, 2007). Such high-throughput analyses
have recently identified new prostate cancer biomarkers, includ-
ing, for example, HEPSIN, EZH2 and a-methyl-Co-racemase
(AMACR) (Dhanasekaran et al, 2001; Jiang et al, 2001; Luo et al,
2001; Magee et al, 2001; Stamey et al, 2001; Varambally et al, 2002;
Rhodes et al, 2003; Parekh et al, 2007). AMACR has first been
found upregulated in prostate cancer by Xu et al (2000) using
suppressive subtractive hybridisation, and AMACR antibodies
have become available quickly thereafter (Jiang et al, 2001; Rubin
et al, 2002). Thus far, it is the only new tissue biomarker of
prostate cancer that has gained clinical acceptance. AMACR is
frequently used in combination with the basal cell markers p63,
CK5/6 and 34-bE12. In diagnostic histopathology, the absence of
these basal cells, which usually line the periphery of normal
prostate glands, is (with very rare exceptions) a defining criterion
of invasive tumour growth (Brawer et al, 1985; Kaleem et al, 1998;
Signoretti et al, 2000). However, it can be difficult to ascertain a
cancer diagnosis in prostate needle biopsies. Use of an additional
positive prostate cancer marker is desirable. AMACR immuno-
histochemistry can show dramatic pictures of strongly positive
cancer glands infiltrating perfectly negative benign prostatic
parenchyma and in these cases its use may turn a diagnosis of
atypical glands into a straightforward diagnosis of cancer (Zhou
et al, 2003, 2004; Epstein, 2004; Epstein and Herawi, 2006). How-
ever, it has been recognised that AMACR may be false-negative in
up to 18% of prostate cancer foci on biopsies and even higher in
some carcinoma subtypes (Epstein, 2004; Zhou et al, 2004).
Recently, GOLPH2 mRNA expression has been reported to be
upregulated in prostate cancer tissues (Luo et al, 2002; Lapointe
et al, 2004; Kristiansen et al, 2005). GOLPH2 is a Golgi
phosphoprotein of yet unknown function that has until very
recently only been described in liver disease as a potential serum
marker of hepatocellular carcinoma (Kladney et al, 2000, 2002a;
Iftikhar et al, 2004; Marrero et al, 2005; Bachert et al, 2007).
GOLPH2 mRNA has recently been described as an integral part of a
multiplex marker to detect prostate cancer from urine samples that
even outperformed a prostate-specific antigen (PSA) blood test
(Laxman et al, 2008).
In this study, we performed a comprehensive GOLPH2 protein
expression analysis in a broad spectrum of normal and malignant
tissues. Further, GOLPH2 expression patterns were studied in
detail in different prostatic lesions. We demonstrate that GOLPH2
protein is upregulated in most prostate cancer cases. In addition to
AMACR and p63, GOLPH2 antibodies will be helpful in the correct
histological diagnosis of prostate cancer. Received 8 May 2008; revised 24 July 2008; accepted 24 July 2008
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sMATERIALS AND METHODS
Data mining of publicly available prostate cancer mRNA
expression data
We interrogated the common gene expression databases, Oncomine
and Arrayexpress, for differential expression of GOLPH2 mRNA in
human prostate cancer and normal tissue (Rhodes et al, 2004;
Parkinson et al, 2007). We identified nine studies within Oncomine
(Dhanasekaran et al, 2001, 2005; Luo et al, 2001, 2002; Vanaja et al,
2003; Lapointe et al, 2004; Varambally et al, 2005; Nanni et al, 2006;
Tomlins et al, 2007) and one study within Arrayexpress (Liu et al,
2006). Altogether, these studies interrogated 305 samples of prostate
cancer in combination with 148 of benign prostate tissues. From the
Oncomine database, the normalised expression values for the nine
studies were extracted and analysed using SPSS.
Prostate cancer patients
Six hundred and fourteen prostate cancer patients who underwent
radical prostatectomy between 1999 and 2005 were enclosed in this
study. Patient age ranged between 43 and 74 years (median 62
years). Preoperative PSA levels ranged from 0.8 to 39ngml
 1
(median 7.2). Forty-four patients (7.2%) had received gonado-
tropin-releasing hormone analogues at the discretion of the
referring urologist before surgery (median 4 weeks, range 2–16
weeks). Clinical follow-up data were assessed annually. Prostate-
specific antigen relapse-free survival time was available for 479
patients. The median follow-up time of all cases was 17 months
(range 1–68 months). The median follow-up time of patients
without a PSA relapse was 18 months (range 4–68 months). Forty-
three patients (9%) experienced a PSA relapse after a median time
of 5 months (range 1–52). The Gleason scores (GS) in the cohort
were distributed as follows: GS 2–6: 217 (35.3%) GS 7: 291 (47.4%),
GS 8–10: 106 (17.3%). Four hundred –and twenty cases had
organ-confined carcinomas (pT2); 191 cases showed extracapsular
tumour extension (pT3). The surgical margins were clear (R0) in
444 cases; 167 cases had positive margins (R1) and 3 cases were Rx.
Use of this tissue has been approved by the Charite’ University
Ethics Committee under the title ‘Retrospektive Untersuchung von
Gewebeproben mittels immunhistochemischer Fa ¨rbung und
molekularbiologischer Methoden’ (‘Retrospective analysis of tissue
samples by immunohistochemistry and molecular biological
techniques’) (EA1/06/2004) on 20 September 2004.
Screening tissue microarray construction
Formalin-fixed and paraffin-embedded material of a representative
variety (185 spots) of normal and malignant human tissues and
tumour cell lines was compiled and assembled on a single block, as
described (Varga et al, 2006).
Prostate tissue microarray construction
Formalin-fixed, paraffin-embedded tissue blocks of radical pros-
tatectomy specimens were selected according to tissue availability
for construction of a TMA. Each case was represented by five tissue
cores. In all cases, benign prostatic hyperplasia (BPH) of the
transitional zone, normal tissue from the peripheral zone, prostatic
intraepithelial neoplasia (PIN), if present (otherwise another core
from the peripheral zone), and two cores of invasive carcinoma,
ideally of primary and secondary GS, were selected for TMA
construction. The core diameter was 1.0mm. All cases were
arranged in 40 TMA recipient paraffin blocks.
Immunohistochemistry
The TMA blocks were freshly cut (3mm) and mounted on super-
frost slides (Menzel Gla ¨ser, Braunschweig, Germany). Immuno-
histochemistry was conducted with the Ventana Benchmark
automated staining system (Ventana Medical Systems, Tucson,
AZ, USA) using Ventana reagents for the entire procedure. To
detect GOLPH2, two commercially available antibodies (mouse
monoclonal, clone 5B10; Abnova Corp., Taipei, Taiwan, catalogue
no. H00051280-M06, dilution 1:1000 and rabbit polyclonal;
Abcam, Cambridge, UK, catalogue no. Ab22209, dilution 1:100)
were diluted in a Ventana diluent. To detect racemase and p63, we
created a cocktail of racemase (rabbit polyclonal; Biologo,
Kronshagen, Germany, dilution 1:30) and p63 (clone mix 4A4/
Y4A3; Neomarkers, Fremont, CA, USA, dilution 1:200) in a
Ventana diluent. Primary antibodies were detected using the
UltraVIEW DAB detection kit using the benchmarks CC1m- heat-
induced epitope retrieval. For the racemase/p63 cocktail, the signal
was further enhanced with the amplification kit. Slides were
counterstained with haematoxylin, dehydrated and mounted.
Evaluation of the immunohistochemical stainings
Chromogenic immunohistochemistry using both GOLPH2 anti-
bodies was primarily conducted on a multitissue array constructed
for antibody testing comprising 185 human tissue spots and cell
lines. The immunostainings were evaluated by two genitourinary
FC = 2.7, P < 0.001
3
2
1
0
GOLPH2 AMACR
100%
80%
60%
40%
20%
0%
N PIN PCa N PIN PCa
N Cap
6
5
4
3
2
1
0
–1
–2
–3
–4
–5
–6
N
o
r
m
a
l
i
z
e
d
 
v
a
l
u
e
Figure 1 GOLPH2 expression in prostate tissues at mRNA and protein
level. (A) Boxplot of the combined normalised expression values of
the nine studies from Oncomine interrogating normal and cancerous
prostate tissues. The fold changes and the respective P-values are indicated
above the brackets. CaP¼prostate cancer tissue; FC¼fold change;
N¼normal prostate. The open circles indicate outliers. (B) Illustration of
the progression of GOLPH2 (on the left) and AMACR expression (on
the right) from normal tissue through PIN to invasive carcinoma
(immunohistochemical data).
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spathologists (GK, FFR) and one histopathology resident (CJ)
simultaneously on a multiheaded microscope.
For both GOLPH2 and racemase, we evaluated staining intensity
with a four-tiered system: 0 (negative), 1þ (weak), 2þþ
(moderate), 3þþþ(strong) in benign tissue, PIN and invasive
carcinoma. To also detect very subtle staining intensity differences,
we further created a dichotomous (‘tumour4normal’) ratio to
better indicate upregulation in tumour in comparison with
adjacent normal tissue. Equal or less GOLPH2 staining intensity
in carcinomatous tissue was reported as ratio 0, higher staining
intensities than in normal glands were regarded as ratio 1.
Heterogeneity of marker expression in invasive carcinoma was
also recorded and diagnosed if more than 25% of the tumour
showed a variation of staining intensity exceeding one scoring
AB
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Figure 2 Characterisation of GOLPH2 antibodies. (A and B) Chromogenic immunocytochemistry of the paraffin-embedded melanoma cell line PF2000.
Both antibodies (A – mouse monoclonal, Abnova; B – rabbit polyclonal, Abcam) show a strong semigranular perinuclear staining, which is suggestive of a
Golgi pattern. (C and D) Immunofluorescent double staining of a prostate cancer gland using both GOLPH2 antibodies (C – mouse monoclonal, D – rabbit
polyclonal). The signal of both antibodies is clearly located to the golgi apparatus, which can now be appreciated by the higher resolution
of immunofluorescence. (E) The colocalisation of the immunoreactivity of both antibodies (plus DAPI staining), which shows that the polyclonal antibody
(red signal) has a less favourable signal to background ratio. (F1) A GOLPH2 immunohistochemistry (monoclonal antibody) of prostate cancer tissue
(lower part – malignant glands, upper part – normal glands) and (F2) a consecutive section of the same case was immunostained after preincubation of the
antibody with an excess of the immunogenic GOLPH2 peptide, which abolishes immunoreactivity.
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scategory. P63 immunoreactivity of the racemase/p63 cocktail was
sometimes used to clearly distinguish benign and malignant
glands.
Monoclonal and polyclonal GOLPH2 double staining by
immunofluorescence
GOLPH2 is a Golgi protein. To better assess the specificity of the
polyclonal and the monoclonal antibody, a double staining by
immunofluorescence was conducted. Primary antibodies (mouse-
anti GOLPH2, Abnova Corp., 1:4000; rabbit-anti GOLPH2, Abcam
Ltd., 1:200) were coincubated on a de-paraffinised prostate tissue
slide after heat-induced antigen retrieval (5min, citrate buffer, pH
6.0, 1101C) at room temperature for 30min. Binding was detected
by fluorescence-labelled secondary antibodies (goat anti-rabbit-
Alexa546 and goat anti-mouse-Alexa488, both from Molecular
probes, catalog nos. A11010 and A11029) under a fluorescence
microscope.
Antibody preincubation with immunogenic peptide
To further assess antibody specificity, the monoclonal antibody
was incubated with an excess of the immunogenic peptide
provided by the antibody supplier (partial recombinant protein
(NP_057632, 302 aa–402 aa) with GST, Abnova Corp.) at 41C
overnight before application to the control tissue (Figure 2F).
Statistical analysis
Statistical analysis was performed using SPSS version 15.0.
P-values o0.05 were considered significant.
RESULTS
GOLPH2 mRNA expression in prostate cancer
We have reported earlier that GOLPH2 mRNA is overexpressed in
microdissected prostate cancer epithelium compared with the
Table 1 GOLPH2 expression in normal and neoplastic human tissues and cell lines
Tissue/cell line (n) GOLPH2  GOLPH2+ GOLPH2++ GOLPH2+++
Normal testis (2) 0 2 0 0
Seminoma (2) 0 1 1 0
Teratoma (2) 0 1 1 0
Placenta (2) 0 2 0 0
Invasive lobular breast carcinoma (4) 0 0 3 1
Invasive ductal breast cancer (4) 0 1 2 1
Cholangiocarcinoma (2) 0 0 1 1
Hepatocellular carcinoma (HCC) (2) 0 0 1 1
Lung adenocarcinoma (1) 0 0 1 0
Lung squamous cell carcinoma (1) 1 0 0 0
Lung small cell carcinoma (1) 0 1 0 0
Serous ovarian carcinoma (2) 1 1 0 0
Ovarian endometrioid carcinoma (1) 0 0 1 0
Ovarian mucinous carcinoma (1) 0 0 1 0
Endometrium endometrioid carcinoma (2) 0 1 0 1
Endometrium serous carcinoma (2) 0 1 1 0
Colon adenocarcinoma (4) 0 1 1 2
GIST (1) 0 0 1 0
Skin squamous cell carcinoma (2) 1 1 0 0
Merkel cell carcinoma (1) 0 1 0 0
Anaplastic oligodendroglioma (1) 0 1 0 0
Anaplastic astrocytoma (1) 0 1 0 0
Glioblastoma multiforme (1) 0 0 1 0
Thyroid papillary carcinoma (2) 0 1 0 1
Thyroid follicular carcinoma (1) 0 0 1 0
Thyoid anaplastic carcinoma (1) 0 0 0 1
Normal kidney (2) 0 2 0 0
Clear cell renal cell carcinoma (4) 0 0 0 2
Papillary renal cell carcinoma (2) 0 0 0 2
Urothelial carcinoma, bladder (4) 0 0 3 1
Adenocarcinoma, prostate (4) 0 0 1 3
Benign prostatic hyperplasia (2) 0 0 2 0
Normal liver (2) 0 2 0 0
Tonsils (3) 0 3 0 0
Non-Hodgkin’s lymphoma (4) 0 2 2 0
Hodgkin’s lymphoma (1) 1 0 0 0
Melanoma (1) 0 1 0 0
HA98 (2) (melanoma) 0 0 2 0
HN2004 (2) (melanoma) 0 0 0 2
PF2000 (2) (melanoma) 0 0 2 0
MET5A (2) (mesothelioma) 0 0 2 0
SW480 (2) (colon cancer) 0 2 0 0
786-O (2) (renal cell cancer) 0 0 0 2
H69 (2) (lung cancer) 0 0 2 0
MCF-7 (2) (breast cancer) 0 0 2 0
SK BR 7 (2) (breast cancer) 0 2 0 0
HELA (2) (cervical cancer) 0 2 0 0
PC3 (2) (prostate cancer) 0 2 0 0
293-T (2) (human embryonal kidney) 0 2 0 0
GOLPH2 in prostate cancer
G Kristiansen et al
942
British Journal of Cancer (2008) 99(6), 939–948 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sadjacent normal prostate epithelium from the same patient by a
fold change of 2.2 (Kristiansen et al, 2005). Liu et al (2006)
described GOLPH2 mRNA as overexpressed by a fold change of
3.14 in their samples (13 normal; 45 cancer), which did not
correlate to tumour differentiation according to GS. A compre-
hensive analysis of the studies from Oncomine combining 260
samples from CaP and 135 from benign prostate normal revealed
an overexpression of GOLPH2 by a factor of 2.7 in prostate cancer
(Po0.001, Figure 1A).
GOLPH2 protein expression in normal and neoplastic
human tissues
Both GOLPH2 antibodies showed identical stainings on a multi-
tissue array comprising 185 tissue spots and cell lines (Figure 2A
and B). Highest rates of GOLPH2 expression were seen not only in
adenocarcinomas of the prostate, colon and breast, but also in
renal cell cancer and hepatocellular carcinoma (Table 1). Prostate
cancer showed the strongest staining.
GOLPH2 expression can be observed in mesenchymal cells and
epithelia, but with strongly differing intensities. As can be expected
from a Golgi-associated protein, it shows a distinct semigranular
dot-like staining pattern and is localised perinuclearly towards
the cell apex in epithelia, whereas the rest of the cytoplasm
is remarkably clear (Figure 2A and B, Figures 3–5). To
further cross-validate antibody specificity, a double immunofluo-
rescent staining using both antibodies was conducted and
demonstrated a clear colocalisation of the antigens in the Golgi
apparatus (Figure 2C–E). Again, the monoclonal and the
polyclonal antibody showed identical staining localisations.
The monoclonal antibody was preferred for further immunostain-
ing our prostate cancer cohort as it yielded slightly less
background and a more intense signal at lower concentrations.
In addition, the preincubation of the monoclonal antibody with an
excess of recombinant GOLPH2 protein completely abolished
immunoreactivity (Figure 2F).
GOLPH2 immunostaining in prostate tissues
Perinuclear GOLPH2 expression is present in normal and
neoplastic prostate glands with unequivocal upregulation in most
hyperplastic and neoplastic glands in comparison with normal
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Figure 3 GOLPH2 expression in prostate tissues. (A) Normal secretory epithelium of normal prostate glands (immunoreactivity score 1þ). (B)
Hyperplastic gland with stronger GOLPH2 expression (score 2þ). (C) Transition of normal epithelium (arrowheads) to high-grade PIN. Note prominent
nucleoli (arrows). This PIN has a strong GOLPH2 immunoreactivity (3þ) and shows an additional diffuse cytoplasmic staining. (D) Gleason 3þ3¼6
adenocarcinoma (central) infiltrating in between normal glands (marked ‘N’). Note the upregulation of GOLPH2 (3þ) in comparison with normal glands.
(E) Same case at a higher magnification. Note the characteristic Golgi pattern. (F) Gleason 3þ3¼6 adenocarcinoma, with a more diffuse cytoplasmic
GOLPH2 staining (3þ). Note neural invasion (lower left). (G) High-grade adenocarcinoma (Gleason score 3þ4¼7) with a strong and coarse GOLPH2
staining (3þ).
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sglands. Some cases of PIN and carcinoma, however, display an
attenuation of the Golgi staining and an additional diffuse strong
cytoplasmic immunoreactivity, which was seen in 68 cases (11.1%)
(Figure 3C and F).
Normal prostatic glands show finely granular GOLPH2 staining,
in some instances with an almost linear pattern (Figure 3A).
The staining intensity is relatively weak yielding a more golden
than brownish DAB precipitate. The median GOLPH2 intensity
in normal tissue was 1þ (Figure 1B). Hyperplastic glands
of BPH show a moderate-to-strong staining intensity (Figure 3B).
Glands with slightly atypical epithelia also show a stronger
immunoreactivity than the normal glands. This becomes
even more pronounced in high-grade PIN (median intensity
2þ) and invasive carcinoma (median intensity 3þ) wherein
the granules are much coarser and stain deeply brown, which
yields a well-discernable contrast to adjacent benign glands
(Figures 3C–G, 5C and F). The statistical differences
between GOLPH2 expression in normal, PIN and carcinoma were
highly significant (Figure 1B; Wilcoxon’s signed rank test,
Po0.001).
GOLPH2 histopathology and survival
GOLPH2 protein expression in prostate cancer was not associated
with pT stage, differentiation grade (GS) and preoperative PSA
levels. There was no association with disease-free survival (Cox
regression, relative risk 0.969, P¼0.910).
GOLPH2 as a potential tool for prostate cancer diagnosis
The most impressive finding of this expression analysis was a
striking difference in GOLPH2 expression in normal and
neoplastic prostate glands. In 237 cases (38.6%), GOLPH2 intensity
was two scoring points higher in tumour epithelia than in normal
glands; in another 324 cases (52.8%), tumoral GOLPH2 expression
excelled by one scoring point; in 51 cases (8.3%), no differences
between normal and tumour were noted; and in only two cases
(0.3%), normal tissue showed a stronger GOLPH2 staining than
adjacent tumour. In summary, 91.4% of cases showed an
upregulation of GOLPH2 in the tumour by at least one scoring
point. This rate is even higher in the separately scored
AMACR/p63 GOLPH2
AB
CD
EF
Figure 4 Comparison between AMACR/p63 and GOLPH2 immunohistochemistry. (A) AMACR expression in invasive cancer glands. Epithelium
of normal glands, with a p63-positive basal cell layer, is AMACR-negative. (B) Sequential section showing GOLPH2 upregulation in matching cancer
glands (score 2þ); adjacent normal glands are weakly GOLPH2-positive (score 1þ). (C) Shows an AMACR-negative example of invasive prostate
cancer, whereas the same tumour has a significant upregulation of GOLPH2 (D) in comparison with normal glands (upper left corner, lower right corner).
The case depicted in (E) and (F) has no included normal glands, but nonetheless a very strong GOLPH2 expression (3þ) that is rarely seen in normal
glands.
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s‘tumour4normal’ ratio. This is able to measure even subtle
differences: 567 of 614 cases (92.3%) had a ratio of 1 and only 47
cases (7.7%) had a ratio of 0.
To characterise GOLPH2 as a new diagnostic tissue marker of
prostate cancer, we conducted a careful comparison with the well-
established AMACR immunohistochemistry. As expected, AMACR
was found overexpressed in high-grade PIN (median score 1þ)
and invasive prostate cancer (median score 2þ), whereas normal
tissues were found to be negative (median score 0) (Figure 1B).
AMACR overexpression in the tumour in direct comparison with
adjacent normal tissue (‘tumour4normal’ ratio) was seen in
95% of cases. AMACR expression was significantly but not
highly correlated to GOLPH2 expression (Table 2, Spearman
rank correlation coefficient 0.113, P¼0.005). However, both
markers also showed remarkable differences, particularly, when
the tumour/normal ratio of GOLPH2 and AMACR was considered.
Here, 26 of 31 AMACR-negative cases (84%) were identified by
GOLPH2. On the other hand, 42 of 47 cases (89%) without
GOLPH2 upregulation were AMACR-positive. Five cases were
concordantly negative and 541 cases were positive for both
markers (Table 3). Four of the five cases, negative for both
markers, were of higher GS. Examples of the comparison of
AMACR and GOLPH2 expression in prostate tissues are shown in
Figures 4 and 5.
The histologically evident intratumoral heterogeneity of prostate
cancer is also reflected in biomarker expression. In this study,
intratumoral AMACR and GOLPH2 heterogeneity of expression
was also evaluated. AMACR has a considerably higher degree of
heterogeneous expression (45% of cases) than GOLPH2 (25%).
This heterogeneity (Figure 4E) can be troublesome in small
tumour foci. In 43 cases, one of two TMA tumour cores was
completely AMACR-negative, whereas the other core of the same
case showed some immunoreactivity. Of these AMACR-negative
cores, GOLPH2 was upregulated in 36 cases (84%).
The combination of GOLPH2 and AMACR showed expression of
either marker in 99.2% of cancer cases, which advocates a
combined use of AMACR and GOLPH2 as positive confirmative
markers of prostate cancer.
F C
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Figure 5 Two examples (A–C, D–F) of prostate needle biopsies (H&E, AMACR/p63, GOLPH2). (A) Prostate needle biopsy with a small focus of a
Gleason 3þ3 adenocarcinoma (arrow). Sequential sections of this focus show a lack of p63-positive basal cells and a moderate AMACR immunoreactivity
(B). GOLPH2 is moderately strongly expressed in these glands, compared with adjacent normal glands (arrowheads), which have a weaker GOLPH2
staining (C). (D) Another example of a prostate needle biopsy with atypical glands, some are macroacinar (arrow), some (lower right) are smaller (*). (E)
The AMACR/p63 cocktail demonstrates a continuous basal cell layer in larger normal gland on top (marked ‘N’), the macroacinar glands directly adjacent to
it and the microacinar proliferates in the lower right corner have no basal cells. In between is a larger gland with a disrupted basal cell layer, probably
diagnostic of a high-grade PIN. All these glands are strongly positive for AMACR and for GOLPH2 (F). It is of importance to note that in this case, both
markers (AMACR and GOLPH2) do not differentiate between the high-grade PIN and the invasive carcinoma.
GOLPH2 in prostate cancer
G Kristiansen et al
945
British Journal of Cancer (2008) 99(6), 939–948 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sDISCUSSION
This is the first report on GOLPH2 (Golgi protein 73, GP73)
protein expression in prostate tissues validated on a large cohort of
clinically detected prostate cancer specimens following radical
prostatectomy. We have recently shown that GOLPH2 mRNA is
among the top upregulated transcripts in prostate cancer
(Kristiansen et al, 2005), which is in line with other profiling
studies (Dhanasekaran et al, 2001, 2005; Luo et al, 2001, 2002;
Vanaja et al, 2003; Lapointe et al, 2004; Varambally et al, 2005; Liu
et al, 2006; Nanni et al, 2006; Tomlins et al, 2007). In our meta-
analysis of publicly available expression data encompassing
260 prostate cancer cases, a mean fold change of 2.7 for GOLPH2
upregulation in cancerous tissues was found. However, a detailed
tissue-based in situ analysis of GOLPH2 protein in prostate tissues
was lacking so far. Very recently, this widely acknowledged
upregulation of GOLPH2 was put into practise: Laxman et al (2008)
included GOLPH2 in a multiplex RT–PCR panel of markers
composed of transcripts known to be overexpressed in prostate
cancer, which, as a urine-based screening test, allows detecting
prostate cancer with a higher sensitivity than a classical PSA
blood test.
GOLPH2 is a 73-kDa Golgi apparatus-associated protein coded
by the gene GOLM1 located on chromosome 9q21.33 and was
originally cloned from a library derived from liver tissue of a
patient with adult giant-cell hepatitis (Kladney et al, 2000). The
initial report also described GOLPH2 expression in a variety of
other human tissues at RNA and protein level and demonstrated
colocalisation of GOLPH2 with giantin, a type II Golgi membrane
protein located at the cis and medial Golgi compartment.
Structurally, GOLPH2 protein consists of a short cytoplasmic N
terminus, a membrane-spanning region, some coiled-coil domains
and a longer luminal C terminus with several potential glycosyl-
ation sites. The functions and the mechanisms of GOLPH2
regulation in normal and neoplastic tissues are still unclear. It
can be generally assumed that it is either involved in post-
translational protein modification, transport of secretory proteins,
cell signalling regulation or simply maintenance of Golgi apparatus
function. Functional assays are necessary to clarify whether
GOLPH2 overexpression confers pro-tumorigenic properties to
tumour cells and how it is regulated. First colocalisation experi-
ments with GPP130, another Golgi marker, hinted at a differential
colocalisation with GOLPH2 in normal and malignant prostate
tissues, which deserves further study. GOLPH2 has several
potential glycosylation sites and up to 75% of GOLPH2 secreted
from hepatocytes is fucosylated, but so far the glycosylation
patterns of GOLPH2 in malignant and normal prostatic epithelia
have not been analysed (Norton et al, 2007).
In the liver cancer cell line HepG2, GOLPH2 was found strongly
upregulated after adenoviral infection, which suggested GOLPH2
as a marker of viral infection in liver tissue and which was
confirmed in following studies incorporating clinical samples
(Kladney et al, 2002a,b). More recently, GOLPH2 was found
upregulated in the serum of patients with hepatocellular carcinoma
(HCC) compared with healthy individuals and has been proposed
as a new serum marker of HCC, which is more sensitive than
a-fetoprotein (Block et al, 2005; Marrero et al, 2005). Apparently,
GOLPH2-overexpressing hepatocytes secrete this normally mem-
brane-bound Golgi protein after cleavage into the serum, which
can be diagnostically utilised (Bachert et al, 2007). We can confirm
the GOLPH2 expression in HCC; however, the finding that
adenocarcinomas of the colorectum, the breast and the prostate
showed equally strong or even stronger immunostainings argues
against GOLPH2/GP73 as a HCC-specific tissue marker. This
finding also implies that further serum analysis of non-HCC cancer
patients, especially prostate cancer patients, is clearly necessary,
before the role of GOLPH2/GP73 as a serum marker specific for
HCC can be further established.
Histological diagnosis of prostate cancer mainly rests on the
conventional parameters of morphological architecture and
cytology. Prostate-specific antigen serum screening has led to
an increase of prostate needle biopsies in the last two decades,
which in turn increased the rate of difficult diagnostic situations
(small carcinoma infiltrates vs benign mimickers of carcinoma)
where immunohistochemical tests are necessary. Loss of basal cells
is a hallmark of prostate cancer; hence, high molecular weight
cytokeratins and p63 have become widely used basal cell tissue
markers. However, even with a loss of basal cells, cancer diagnosis
can be problematic in some cases. Additional markers of prostate
cancer are desirable. So far only AMACR/racemase has gained
wider acceptance as a positive marker of prostate cancer, although
is has two well-known limitations: intratumoral heterogeneity,
which was confirmed in 45% of our cases, and AMACR-negative
carcinomas (Wang et al, 2006; Murphy et al, 2007). In our series,
31 completely AMACR-negative carcinomas (5%) and another
43 cases (7%), in which one of both tumour cores on the TMA was
Table 2 GOLPH2 protein expression in prostate cancer
GOLPH2 expression
1+ 2+ 3+ P-value
All cases 10 (1.6%) 275 (44.8%) 329 (53.6%)
Age 0.321
p62 6 (1.9%) 143 (46.3%) 160 (51.8%)
462 4 (1.3%) 132 (43.3%) 169 (55.4%)
Pre-OP PSA
a 0.475
p10ngml
 1 5 (1.1%) 197 (44.6%) 240 (54.3%)
410ngml
 1 5 (3.0%) 73 (44.2%) 87 (52.7%)
pT status 0.267
pT2 8 (1.9%) 194 (45.9%) 221 (52.2%)
pT3/4
b 2 (1.0%) 81 (42.4%) 108 (56.5%)
Gleason score 0.264
3–6 1 (0.5%) 92 (42.4%) 124 (57.1%)
7 7 (2.4%) 136 (46.7%) 148 (50.9%)
8–10 2 (1.9%) 47 (44.3%) 57 (53.8%)
Residual tumour
c 0.457
R0 6 (1.4%) 206 (46.4%) 232 (52.3%)
R1 4 (2.4%) 68 (40.7%) 95 (56.9%)
AMACR expression 0.005
0 2 (10.5%) 7 (36.8%) 10 (52.6%)
1+ 3 (3%) 53 (52.5%) 45 (44.6%)
2+ 2 (0.6%) 152 (47.2%) 168 (52.2%)
3+ 3 (1.7% 63 (36.6%) 106 (61.6%)
Abbreviations: AMACR¼a-methylacyl-CoA racemase; Pre-OP PSA¼preoperative
PSA; pT-status¼tumour stage.
aPreoperative PSA was not available for seven cases.
bOne case was pT4.
cThree cases were Rx.
Table 3 Tumour/normal ratio of AMACR and GOLPH2 expression in
prostate cancer
GOLPH2 tumour4normal
No Yes Total AMACR
AMACR tumour4normal
No 5 26 31 (5%)
Yes 42 541 583 (95%)
Total GOLPH2 47 (7.7%) 567 (92.3%)
Abbreviation: AMACR¼a-methylacyl-CoA racemase.
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considered negative on a needle biopsy, an additional GOLPH2
immunostaining would have allowed a cancer diagnosis in 84% of
cases. This is partially because of the considerably lower rate of
intratumoral heterogeneity of GOLPH2, which was 25% in our
series. These findings clearly advocate the use of GOLPH2 as an
additional ancillary positive marker for the histological detection
of prostate cancer. Comparable with the introduction of AMACR,
we would expect that the number of unclear cases can be further
lowered by GOLPH2, which would help to avoid costly and
unnecessary rebiopsies (Jiang et al, 2004). Although GOLPH2
immunostaining is not as easy to read as an AMACR staining at
first sight, mainly because of the physiological basal GOLPH2
expression in normal tissues, we think that the internal positive
control of immunoreactivity in normal tissues can also be seen as
an advantage. In addition, the characteristic Golgi pattern is
another indicator of specific immunoreactivity, whereas a general
overstaining of a slide is often more diffusely cytoplasmic.
In spite of our comprehensive description of GOLPH2 as a
positive marker of malignancy, we would hesitate to recommend
using GOLPH2 as the primary second-line antibody after basal
cell markers for determining malignancy. First, its sensitivity is
slightly lower (92.3%) than AMACR (95.0%), which is, of course,
compensated for by its higher homogeneity. Secondly, and more
importantly, definition of a positive test result requires adjacent
normal glands for direct comparison. As high-grade PIN and
hyperplastic benign glands can also show GOLPH2 upregulation,
it can be difficult, or even impossible, to diagnose an atypical
focus that lacks adjacent normal glands by GOLPH2 immuno-
histochemistry alone. The comparison with normal tissue is
mandatory to obtain a valid result. Another caveat stems from
the construction of our TMA, which has been compiled after
central review of 640 fully embedded prostatectomy specimens to
allow an immunohistochemical evaluation of representative
normal and tumour tissue. Benign cancer mimickers, which can
be particularly problematic to diagnose on needle biopsies, were
not intentionally sampled. Further validation of the diagnostic
value of GOLPH2 in rare cancer variants and benign cancer
mimickers is necessary.
In summary, this study is the first to comprehensively confirm
at protein level the GOLPH2 upregulation in prostate cancer,
which has been suggested in preceding mRNA profiling studies.
The high rate of GOLPH2 protein overexpression, which is also
seen in AMACR-negative prostate cancer cases, suggests its use as
an additional ancillary positive tissue marker of prostate cancer.
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